» Articles » PMID: 17356471

Hematologic Effects of Maternal Antiretroviral Therapy and Transmission Prophylaxis in HIV-1-exposed Uninfected Newborn Infants

Overview
Date 2007 Mar 16
PMID 17356471
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: A prospective observational study to investigate hematologic alterations during the first 3 months of life in HIV-exposed uninfected infants subjected to antiretroviral medication before and after birth.

Methods: Two hundred twenty-one consecutive uninfected infants born to HIV-positive mothers on antiretroviral medication during pregnancy were included. Perinatal transmission prophylaxis comprised zidovudine (ZDV) administered intravenously intrapartum and 10 days after birth. Blood counts and differentials were determined at birth and at 2, 4, 6, and 12 weeks of age, and hematologic toxicity was graded according to pediatric toxicity scales. Data were analyzed according to the kind of prenatal medication (ZDV alone or with another nucleoside reverse transcriptase inhibitor [NRTI] vs. highly active antiretroviral therapy [HAART]).

Results: Median hemoglobin was significantly lower in HAART-exposed newborns from birth (P = 0.004) until day 28. During follow-up, 119 (53.8%) infants had anemia grade 2 or higher on at least 1 occasion; 16 (7.2%) received red blood cell transfusion at 23 (range: 1-56) days of age. Neutropenia grade 2 or higher occurred in 106 (48.0%) infants at least once; 8 infants had staphylococcal infections, and 2 infections were severe. After adjustment for possible confounders (prematurity, birth weight, ethnicity, gender, duration of maternal antiretroviral therapy, maternal Centers for Disease Control and Prevention stage, and maternal illicit drug use), HAART exposure was the only independent risk factor for anemia (odds ratio [OR] = 2.22, 95% confidence interval [CI]: 1.06 to 4.64; P = 0.034) and neutropenia (OR = 2.15, CI: 1.02 to 4.55; P = 0.045).

Conclusions: Antiretroviral transmission prophylaxis is associated with significant anemia and neutropenia in HIV-uninfected infants during the first 3 months of life. Anemia was more profound in HAART-exposed infants.

Citing Articles

The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action.

Fioredda F, Skokowa J, Tamary H, Spanoudakis M, Farruggia P, Almeida A Hemasphere. 2023; 7(4):e872.

PMID: 37008163 PMC: 10065839. DOI: 10.1097/HS9.0000000000000872.


Virus Etiology, Diversity and Clinical Characteristics in South African Children Hospitalised with Gastroenteritis.

Rossouw E, Brauer M, Meyer P, du Plessis N, Avenant T, Mans J Viruses. 2021; 13(2).

PMID: 33573340 PMC: 7911269. DOI: 10.3390/v13020215.


Role of Inflammation in Virus Pathogenesis during Pregnancy.

Chudnovets A, Liu J, Narasimhan H, Liu Y, Burd I J Virol. 2020; 95(2).

PMID: 33115865 PMC: 7944452. DOI: 10.1128/JVI.01381-19.


Infant Neutropenia Associated with Breastfeeding During Maternal Antiretroviral Treatment for Prevention of Mother-to-Child Transmission of HIV.

Njuguna I, Reilly M, Jaoko W, Gichuhi C, Ambler G, Maleche-Obimbo E Retrovirology (Auckl). 2019; 6:1-5.

PMID: 31708646 PMC: 6839413. DOI: 10.4137/RRt.s13267.


Safety of tenofovir during pregnancy: early growth outcomes and hematologic side effects in HIV-exposed uninfected infants.

Seidel V, Weizsacker K, Henrich W, C Rancourt R, Buhrer C, Kruger R Eur J Pediatr. 2019; 179(1):99-109.

PMID: 31659467 DOI: 10.1007/s00431-019-03481-x.